Trial Profile
Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms VICTORY-J
- 01 Feb 2020 Status changed from active, no longer recruiting to completed according to results published in the Cancer Science.
- 01 Feb 2020 Results published in the Cancer Science
- 01 Feb 2018 Planned End Date changed from 1 Mar 2017 to 20 Feb 2018.